Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) hit a new 52-week high on Friday . The company traded as high as $6.04 and last traded at $5.68, with a volume of 53291 shares. The stock had previously closed at $5.87.
ADAP has been the topic of a number of research analyst reports. Mizuho began coverage on shares of Adaptimmune Therapeutics in a research report on Tuesday, April 21st. They set a “neutral” rating and a $3.00 price target on the stock. BidaskClub upgraded Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. SVB Leerink reaffirmed a “market perform” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, May 14th. Zacks Investment Research lowered Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Citigroup reduced their price objective on shares of Adaptimmune Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, April 27th. Four analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $5.19.
The company has a 50 day moving average price of $3.69 and a 200 day moving average price of $2.73. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.64 and a quick ratio of 7.64.
Several hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its position in shares of Adaptimmune Therapeutics by 5,820.4% during the first quarter. Tower Research Capital LLC TRC now owns 9,591 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 9,429 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Adaptimmune Therapeutics during the 1st quarter valued at about $34,000. Raymond James & Associates lifted its position in Adaptimmune Therapeutics by 13.7% in the 4th quarter. Raymond James & Associates now owns 29,411 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,546 shares during the last quarter. Partnervest Advisory Services LLC purchased a new stake in Adaptimmune Therapeutics in the fourth quarter worth approximately $42,000. Finally, Invesco Ltd. bought a new position in Adaptimmune Therapeutics during the first quarter valued at approximately $47,000. Institutional investors own 50.59% of the company’s stock.
Adaptimmune Therapeutics Company Profile (NASDAQ:ADAP)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Story: What does a bar chart display?
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.